This company listing is no longer active
3TP0 Stock Overview
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acerus Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$7.90 |
| 52 Week Low | US$0.14 |
| Beta | 0.99 |
| 1 Month Change | 0% |
| 3 Month Change | -77.36% |
| 1 Year Change | -95.31% |
| 3 Year Change | -91.05% |
| 5 Year Change | -99.37% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3TP0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.0% | 1.3% |
| 1Y | -95.3% | -25.6% | 6.4% |
Return vs Industry: 3TP0 underperformed the German Pharmaceuticals industry which returned 3.3% over the past year.
Return vs Market: 3TP0 underperformed the German Market which returned -2.5% over the past year.
Price Volatility
| 3TP0 volatility | |
|---|---|
| 3TP0 Average Weekly Movement | 34.8% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3TP0's share price has been volatile over the past 3 months.
Volatility Over Time: 3TP0's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 14 | Ed Gudaitis | https://www.aceruspharma.com |
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis.
Acerus Pharmaceuticals Corporation Fundamentals Summary
| 3TP0 fundamental statistics | |
|---|---|
| Market cap | €2.62m |
| Earnings (TTM) | -€26.54m |
| Revenue (TTM) | €2.87m |
0.6x
P/S Ratio-0.1x
P/E RatioIs 3TP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3TP0 income statement (TTM) | |
|---|---|
| Revenue | US$3.04m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.71m |
| Other Expenses | US$29.79m |
| Earnings | -US$28.08m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.64 |
| Gross Margin | 56.32% |
| Net Profit Margin | -924.33% |
| Debt/Equity Ratio | -329.8% |
How did 3TP0 perform over the long term?
See historical performance and comparison